Compound News and Research

RSS

Napp introduces new alcohol-free hand sanitizer

Soft & Shield Hand Sanitizer and Moisturizer is a new alcohol-free hand sanitizer that contains ingredients that soften, smooth and moisturize the skin. As an added benefit, the Soft & Shield Hand Sanitizer and Moisturizer forms an invisible protective barrier that covers the outer layer of the skin to protect for up to four hours against harmful germs and bacteria.

11 May 2010

MediciNova announces $15 million senior secured term loan with Oxford Finance

MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today announced that it has entered into a $15 million senior secured term loan with Oxford Finance Corporation.

11 May 2010

Transition Therapeutics reports increased revenue in third-quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended March 31, 2010.

11 May 2010

Forest, Almirall to present data on aclidinium bromide for COPD and LAS100977 for asthma at ATS conference

Forest Laboratories, Inc. and Almirall, S.A. today announced that they are presenting data from several studies of two investigational inhaled respiratory compounds at the annual American Thoracic Society International Conference taking place in New Orleans May 14-19, 2010. Data on aclidinium bromide, an inhaled muscarinic antagonist, which is in Phase III development for COPD, and LAS100977, a long-acting beta 2-agonist, in Phase II development for asthma, will be presented in 11 separate posters.

11 May 2010

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the first quarter ended March 31, 2010.

11 May 2010

Nurse fatigue and patient safety

A disturbing report highlighting the extent to which nurses across the country are experiencing fatigue on the job points to the need for changes in the workplace to ensure patient safety isn't compromised.

11 May 2010

Merck, Glenmark settle ZETIA patent litigation

Merck & Co., Inc. and Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals, Ltd. have reached an agreement to settle their patent litigation involving Glenmark's challenge to Merck's patent covering ZETIA ® (ezetimibe). Specifically, Glenmark challenged Merck's basic compound patent, RE 37,721 (the "721 patent") on numerous grounds.

11 May 2010

Enzon reports income from continuing operations of $20.8M for first-quarter 2010

Enzon Pharmaceuticals, Inc. today announced its financial results for the first quarter of 2010. During the quarter, the Company completed the sale of its specialty pharmaceutical business. This transaction has now transformed the Company, both financially and operationally, into a biopharmaceutical company dedicated to the discovery and development of oncology medicines.

10 May 2010

Achillion reports lower net loss of $5.6M for first-quarter 2010

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three months ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $5.6 million or $0.16 per share, compared with a net loss of $6.7 million or $0.25 per share for the first quarter of 2009. Cash, cash equivalents and marketable securities as of March 31, 2010 were $25.0 million, up $15.3 million compared with December 31, 2009.

10 May 2010

Findings may help develop a new class of drugs for diabetes

More than half a century after researchers identified a promising way to treat diabetes based on blocking the breakdown of insulin in the body, a research team led by a scientist at the Mayo Clinic campus in Florida have developed potent molecules that can do just that.

10 May 2010

Icagen reports revenues of $1.5M, net loss of $3.2M for first-quarter 2010

Icagen, Inc. reported today its financial results and operational highlights for the first quarter ended March 31, 2010. For the first quarter of 2010, the Company reported revenues of $1.5 million and a net loss of $3.2 million. As of March 31, 2010, the Company's cash and cash equivalents totaled $14.3 million.

7 May 2010

Meda acquires exclusive rights for use of flupirtine to treat fibromyalgia from Adeona Pharmaceuticals

Meda has acquired exclusive US, Canadian and Japanese rights for the use of flupirtine to treat fibromyalgia from Adeona Pharmaceuticals. As part of the agreement, Meda is taking over full responsibility for development and commercialization of the compound. Flupirtine is currently in phase II development for the patented indication fibromyalgia.

7 May 2010

54% of liver cirrhosis patients experience neurocognitive impairments

More than half of patients who have cirrhosis of the liver also display neurocognitive impairments such as short term memory loss, a study led by a Loyola University Health System researcher has found.

7 May 2010

Amira Pharmaceuticals' LPA1 receptor antagonist program data published in British Journal of Pharmacology

Amira Pharmaceuticals, Inc. announced today that preclinical data from its LPA1 receptor antagonist program has been published in the British Journal of Pharmacology.

7 May 2010

Affymax reduces net loss to $7.9 million for first-quarter 2010

Affymax, Inc. today reported financial results for the first quarter ended March 31, 2010. The net loss for the first quarter of 2010 was $7.9 million compared to a net loss of $21.7 million for the first quarter of 2009.

6 May 2010

Curis reports net income of $4.8M for first-quarter 2010

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the first quarter ended March 31, 2010.

6 May 2010

Momenta Pharmaceuticals first-quarter net loss decreases to $16.1 million

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results for the quarter ended March 31, 2010.

6 May 2010

Aeterna Zentaris granted FDA orphan-drug designation for AEZS-108 in ovarian cancer

Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation for AEZS-108, its doxorubicin targeted conjugate compound, for the treatment of ovarian cancer. AEZS-108 is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.

6 May 2010

CombinatoRx reports $41.3M total revenue for first-quarter 2010

CombinatoRx, Incorporated today reported financial results for the first quarter ended March 31, 2010.

6 May 2010

Researchers demonstrate how Plasmodium falciparum can able to circumvent action of artemisinin

Researchers from CNRS, INSERM and Toulouse University Hospital have demonstrated how the parasite Plasmodium falciparum, which causes severe forms of malaria, is able to circumvent the action of artemisinin and its derivatives, which are today the first-line drugs used to treat this disease. This study supplies some important findings that will enable a clearer understanding of the mechanisms of resistance to antimalarial drugs and the testing of novel therapeutic strategies in a context where the drug resistance of parasites is of increasing concern.

6 May 2010